EXFERANA 180MG Potahovaná tableta Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

exferana 180mg potahovaná tableta

vipharm s.a., ożarów mazowiecki array - 16626 deferasirox - potahovaná tableta - 180mg - deferasirox

EXFERANA 360MG Potahovaná tableta Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

exferana 360mg potahovaná tableta

vipharm s.a., ożarów mazowiecki array - 16626 deferasirox - potahovaná tableta - 360mg - deferasirox

EXFERANA 90MG Potahovaná tableta Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

exferana 90mg potahovaná tableta

vipharm s.a., ożarów mazowiecki polsko - 16626 deferasirox - potahovaná tableta - 90mg - deferasirox

Clopidogrel Acino Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

clopidogrel acino

acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotické činidla - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Kaftrio Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

kaftrio

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystická fibróza - jiné produkty dýchacích cest - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Retsevmo Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastická činidla - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

BISEPTOL 80MG/ML+16MG/ML Koncentrát pro infuzní roztok Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

biseptol 80mg/ml+16mg/ml koncentrát pro infuzní roztok

zaklady farmaceutyczne polpharma sa, starogard gdański array - 1395 sulfamethoxazol; 1490 trimethoprim - koncentrát pro infuzní roztok - 80mg/ml+16mg/ml - sulfamethoxazol a trimethoprim

SUMETROLIM 40MG/ML+8MG/ML Sirup Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

sumetrolim 40mg/ml+8mg/ml sirup

egis pharmaceuticals plc, budapešť array - 1395 sulfamethoxazol; 1490 trimethoprim - sirup - 40mg/ml+8mg/ml - sulfamethoxazol a trimethoprim

SUMETROLIM 400MG/80MG Tableta Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

sumetrolim 400mg/80mg tableta

egis pharmaceuticals plc, budapešť array - 1395 sulfamethoxazol; 1490 trimethoprim - tableta - 400mg/80mg - sulfamethoxazol a trimethoprim